- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| VITA LIFE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 19.12.25 | VITA LIFE SCIENCES LIMITED: Notification of cessation of securities - VLS | - | ASX | ||
| 17.12.25 | VITA LIFE SCIENCES LIMITED: Change of Director's Interest Notice | - | ASX | ||
| 11.12.25 | VITA LIFE SCIENCES LIMITED: Profit Guidance | - | ASX | ||
| 11.12.25 | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 10.12.25 | VITA LIFE SCIENCES LIMITED: Notification of cessation of securities - VLS | - | ASX | ||
| 04.12.25 | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 24.11.25 | VITA LIFE SCIENCES LIMITED: Notification of cessation of securities - VLS | 1 | ASX | ||
| 19.11.25 | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 18.11.25 | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 12.11.25 | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 06.11.25 | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 04.11.25 | VITA LIFE SCIENCES LIMITED: Notification of cessation of securities - VLS | - | ASX | ||
| 31.10.25 | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 30.10.25 | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 28.10.25 | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 27.10.25 | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 26.10.25 | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 23.10.25 | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 22.10.25 | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX | ||
| 21.10.25 | VITA LIFE SCIENCES LIMITED: Update - Notification of buy-back - VLS | - | ASX |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GREEN THUMB INDUSTRIES | 5,615 | -1,49 % | Why Green Thumb Industries Could Be Among the Biggest Winners From Marijuana Rescheduling | ||
| ALNYLAM PHARMACEUTICALS | 285,20 | +0,04 % | Should You Buy Alnylam Pharmaceuticals Before Feb. 12? | ||
| NEKTAR THERAPEUTICS | 31,600 | 0,00 % | Where Nektar Therapeutics Stands With Analysts | ||
| CASSAVA SCIENCES | 1,701 | +1,58 % | Cassava Sciences, Inc.: Cassava Announces Agreement to Settle Securities Class Action Litigation | AUSTIN, Texas, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, "Cassava", the "Company"), a biotechnology company focused on developing novel, investigational treatments for... ► Artikel lesen | |
| ADASTRA | 0,108 | +0,93 % | Adastra Holdings Ltd.: Adastra Holdings Announces Completion of Sale of Subsidiaries | Langley, British Columbia--(Newsfile Corp. - October 15, 2025) - Adastra Holdings Ltd. (CSE: XTRX) (FSE: D2E0) (the "Company") announces that it has completed the sale of all of the issued and outstanding... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 3,130 | -1,73 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) | Contract Research Organization for the REGAL trial has informed the Company that 72 events have occurred in the trial as of December 26, 2025; SELLAS remains blinded to trial outcomesTiming of the... ► Artikel lesen | |
| ACADIA PHARMACEUTICALS | 21,150 | -0,28 % | XFRA DR6: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 20,670 | +0,78 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update | Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Guidance... ► Artikel lesen | |
| MOLECULE HOLDINGS | 0,001 | 0,00 % | Molecule Holdings Inc. Provides Corporate Update | ||
| NUMINUS WELLNESS | 0,027 | -100,00 % | Numinus Wellness Inc.: Numinus Wellness Provides Corporate Update | Vancouver, British Columbia--(Newsfile Corp. - December 1, 2025) - Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative... ► Artikel lesen | |
| ZELIRA THERAPEUTICS | 0,348 | -15,94 % | ZELIRA THERAPEUTICS LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | ||
| SOLIGENIX | 1,245 | -4,96 % | SOLIGENIX, INC.: Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford) | Study results support advancing SGX945 in this difficult-to-treat orphan disease
Results suggest potential durability of response for maintenance therapy
PRINCETON, N.J., Dec. 18... ► Artikel lesen | |
| ANI PHARMACEUTICALS | 67,00 | -3,60 % | Aktien New York: Dow stabilisiert sich - S&P 500 setzt Rekordkurs fort | NEW YORK (dpa-AFX) - Die US-Aktienmärkte haben am Montag ihre anfänglich moderaten Verluste im Handelsverlauf aufgeholt und tendieren leicht im Plus. Zunächst hatte der sich weiter zuspitzende Streit... ► Artikel lesen | |
| OPUS GENETICS | 1,930 | -0,62 % | Opus Genetics, Inc.: Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa | The trial is funded through Abu Dhabi's Healthcare Research and Innovation FundClinical development activities will commence at Cleveland Clinic Abu Dhabi in 2026MERTK-related retinitis pigmentosa... ► Artikel lesen | |
| THC BIOMED | 0,011 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 23.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 23.09.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 23.09.2025.ISIN NameAU0000221251 LEO... ► Artikel lesen |
Das Unternehmen VITA LIFE SCIENCES LIMITED kann der Branche Pharma zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VITA LIFE SCIENCES LIMITED finden Sie auf Wallstreet Online.